堃博醫療-B(2216.HK)漲近9% 領漲醫療器械板塊
格隆匯3月10日丨港股醫療器械股普漲,其中,堃博醫療-B(2216.HK)漲近9%報3.19港元,最新市值16.8億港元。堃博醫療是全球創新肺部介入診療器械先行者。在港股醫療器械領域,堃博醫療是唯一一家專注於肺部、擁有肺部介入診療技術的公司,提供針對介入性肺病的診斷和治療的產品組合。其所在的介入呼吸病學市場有着極高的准入壁壘。據悉,堃博醫療目前有多項產品獲得國家藥監局審核、美國FDA和歐盟CE認證。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.